Elacestrant Dihydrochloride

Drug Overview

Elacestrant dihydrochloride is a selective estrogen receptor degrader (SERD). It is an oral, non-steroidal drug used to treat estrogen receptor (ER)-positive breast cancer. Its ability to effectively degrade the ER protein makes it a significant advance in endocrine therapy and a prime example of a Targeted Therapy.

• Generic Name: Elacestrant dihydrochloride
• US Brand Names: Orserdu®
• Drug Class: Selective Estrogen Receptor Degrader (SERD), Endocrine Therapy
• Route of Administration: Oral Tablet
• FDA Approval Status: Approved for the treatment of postmenopausal women or men with advanced or metastatic ER-positive, HER2-negative breast cancer with an ESR1 mutation, whose disease has progressed following at least one line of endocrine therapy.

What Is It and How Does It Work? (Mechanism of Action)

Elacestrant acts by binding directly to the estrogen receptor (ER) in cancer cells, causing the receptor to change shape and be tagged for destruction, thus removing the primary growth stimulus for the cancer.

• Molecular Target (Estrogen Receptor): Elacestrant targets the estrogen receptor (ER), particularly the ER alpha isoform, which is the key driver of proliferation in ER-positive breast cancer.
• Action (Receptor Degradation): Elacestrant binds to the ER and induces a conformational change in the receptor protein. This change marks the ER for degradation via the ubiquitin-proteasome pathway within the cell, leading to a significant reduction in total ER protein levels.
• Result (Growth Inhibition): The degradation of the ER prevents estrogen signaling, thereby blocking the downstream genetic transcription necessary for tumor cell growth and proliferation.
• Bone Affinity: Not applicable. Elacestrant is a systemic oral endocrine therapy agent and does not possess selective affinity for bone components.

FDA Approved Clinical Indications

Elacestrant has a highly precise indication, focusing on a specific molecular subset of metastatic breast cancer defined by a resistance mutation.

Oncological Uses

1. Metastatic ER-Positive Breast Cancer: Indicated for postmenopausal women or men with advanced or metastatic ER-positive, HER2-negative breast cancer that has an ESR1 mutation, and whose disease has progressed following at least one line of endocrine therapy.

Non-oncological Uses

1. There are currently no FDA-approved non-oncological indications for Elacestrant dihydrochloride.
2. Its targeted mechanism is specific to the estrogen receptor pathway in malignancy.

Dosage and Administration Protocols

Elacestrant is administered as a continuous oral tablet once daily.

• Dose Reduction: Dose reduction is required for managing treatment-emergent adverse events, notably severe nausea, vomiting, or elevated liver enzymes. Dose reduction steps are typically 258 mg, then 172 mg daily.
• Renal Insufficiency: No dose adjustment is required for mild to moderate renal impairment. Use with caution in severe renal impairment.
• Hepatic Insufficiency: Dose reduction (initial dose of 258 mg) is required for patients with mild hepatic impairment (Child-Pugh A). The initial dose should be further reduced (to 172 mg) for moderate hepatic impairment (Child-Pugh B). It is not recommended for severe hepatic impairment (Child-Pugh C).

Standard Dosing for Oncological Indications (Metastatic Breast Cancer)

Clinical Efficacy and Research Results

Elacestrant’s approval is based on its demonstration of improved survival specifically in patients whose tumors harbored ESR1 mutations, a major driver of resistance.

• Metastatic Breast Cancer (EMERALD Trial – 2020-2025 Context): This Phase III trial compared Elacestrant monotherapy against standard-of-care (SOC) endocrine therapy (fulvestrant or an aromatase inhibitor).
• Progression-Free Survival (PFS): In the overall population, Elacestrant showed a modest increase in median PFS (2.79 months vs. 2.01 months for SOC).
• PFS in ESR1-Mutated Patients: Critically, in the primary subgroup of patients with the ESR1 mutation (the approved indication), Elacestrant significantly extended median PFS to 3.8 months compared to 1.9 months for SOC. This represents a 45 percent reduction in the risk of progression or death (Hazard Ratio of 0.55).
• 12-Month Survival: In the ESR1-mutated group, the rate of patients alive and without progression at 12 months was 22.3 percent for Elacestrant versus 9.4 percent for SOC, demonstrating durable benefit.

Safety Profile and Side Effects

Black Box Warning

Elacestrant is generally well-tolerated compared to chemotherapy, with the most common side effects being gastrointestinal in nature.

Common Side Effects (Greater than 10 percent)

• Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.
• Systemic: Fatigue, musculoskeletal pain.
• Laboratory Abnormalities: Increased cholesterol, increased AST and ALT (liver enzymes).

Serious Adverse Events

1. Hepatotoxicity: Severe liver enzyme elevation (Grade 3/4) requiring dose interruption or permanent discontinuation.
2. Hypercholesterolemia: Significant elevations in serum cholesterol and triglycerides.
3. Hypersensitivity Reactions: Rare, but serious hypersensitivity reactions, including urticaria and angioedema.

Connection to Stem Cell and Regenerative Medicine

Elacestrant is connected to regenerative medicine through its ability to offer a non-chemotherapy option that preserves the patient’s long-term health and cellular fitness.

• Supportive Endocrine Regeneration: By providing an effective, oral, non-cytotoxic therapy that overcomes resistance, Elacestrant preserves the patient’s quality of life and immune system integrity. This is crucial for elderly or frail patients who cannot tolerate aggressive treatments, effectively regenerating the functional status and capacity for long-term health management.
• Bone Health: Although not a direct bone agent, controlling metastatic breast cancer (which often metastasizes to bone) through effective systemic therapy indirectly supports bone health and reduces the incidence of skeletal-related events (SREs).

Patient Management & Practical Recommendations

Pre-treatment Tests to Be Performed

Patient management focuses on managing gastrointestinal side effects and ensuring correct administration to optimize drug absorption.

• Genetic Testing: Mandatory confirmation of the ESR1 mutation in tumor tissue using a validated test (e.g., liquid biopsy or tissue sequencing).
• Organ Function: Baseline Liver Function Tests (LFTs) and Renal Function Assessment.

Precautions During Treatment

• Administration: The drug must be taken with food to ensure adequate and consistent absorption.
• Antiemetics: Proactive prescribing of antiemetics for nausea, particularly during the first cycle.

Do’s and Don’ts List

• DO report persistent nausea, vomiting, or yellowing of the skin/eyes (jaundice) immediately.
• DO adhere to all scheduled monitoring appointments for LFTs and lipid panels.
• DON’T take the medication without confirmation of the ESR1 mutation status.
• DON’T consume grapefruit or grapefruit juice, as they can interfere with drug metabolism.

Legal Disclaimer

The information provided herein regarding Elacestrant dihydrochloride (Orserdu®) is intended for general informational purposes only and is directed towards an international audience of patients and healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or personalized treatment from a qualified oncologist. This drug involves risks including hepatotoxicity and must only be used in patients with confirmed ESR1 mutations. All individuals must consult their specific healthcare provider for information tailored to their medical condition and treatment regimen. Reliance on any information appearing on this guide is solely at your own risk.